US FTC to scrutinize drug patents listed in FDA Orange Book; improper listings may be litigated, official warns
Pharmaceutical companies were put on notice today by a senior Federal Trade Commission enforcer over improperly listed patents that the agency says could chill generic drug competition in the US, with...To view the full article, register now.
Already a subscriber? Click here to view full article